NovoCure Reports Second Quarter 2016 Financial Results and Provides Company Update

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today reported financial results for the quarter ended June 30, 2016, highlighting year-over-year growth in prescriptions, active patients and reported revenues.

Back to news